NeuroVoices: Katherine Peters, PhD, on Vorasidenib’s Impact on Quality of Life, Neurocognition, and Seizures in the Treatment of Gliomas

K Peters

Dr. Peters provides clarity on a new analysis of the INDIGO study highlighting treatment benefits of vorasidenib in patients with IDH mutant grade 2 gliomas.

Share